# About Tirzepatide / Get — An Independent Editorial Field Manual

> Tirzepatide / Get is an independent editorial publisher that summarizes the peer-reviewed tirzepatide research literature and the FDA regulatory record. Not a clinic, not a pharmacy, not a telehealth platform.

Who publishes this site, what we do, what we explicitly do not do, and how to read the manual responsibly.

## What this site is

Tirzepatide / Get is an independent editorial project that publishes plain-language summaries of the peer-reviewed research literature on tirzepatide and the FDA regulatory record governing it.

The site is organized as an illustrated field manual — a chapter on what the molecule is, a chapter on the dual-incretin mechanism, chapters on the SURPASS, SURMOUNT, SURMOUNT-OSA, SUMMIT, and SYNERGY-NASH trial programs, a chapter on the FDA-labeled dose-escalation schedule, an FAQ covering the questions that bring most readers here, and a full reference list. Every quantitative claim on the site links back to a primary source in that reference list.

## What this site explicitly is not

Tirzepatide / Get is **not a clinic**. It does not employ clinicians and it does not provide medical advice.

It is **not a pharmacy**. It does not manufacture, sell, distribute, or dispense any product.

It is **not a telehealth platform**. It does not match readers with prescribers, take payment, or facilitate the acquisition of any medication.

The word *get* in the domain name is a search-intent signal — readers typing it are typically looking for a plain-language explanation of what tirzepatide is, what the evidence base looks like, and what the lawful access pathway in the United States looks like in the wake of the October 2024 shortage resolution. The site answers those questions editorially. Any decision about whether tirzepatide is appropriate for an individual person is made by that person and a licensed clinician who knows their medical history.

## Editorial standards

**Sources.** Every quantitative claim is cited to a primary source — the published journal article for a trial result, the FDA prescribing information for a labeled dose or warning, or the FDA's own regulatory documents for the shortage-resolution timeline. Secondary commentary is used sparingly and labeled when it appears.

**Brand names.** This site uses only the international nonproprietary name (INN) *tirzepatide*. Brand names assigned to tirzepatide-containing products are not used in the body copy. This is an editorial choice: a generic-name-only register keeps the site focused on the molecule and the evidence rather than on commercial branding.

**No recommendations.** The site describes what trials measured and what the label specifies. It does not recommend doses, indications, treatment durations, or any other clinical decision. Third-person, study-attributed language is the default register throughout.

**No anecdote.** Personal stories, reader testimonials, and unsourced claims do not appear on this site. The voice is an instructional one — a friendly teacher walking the reader through what the literature contains — and an instructional voice means citing where every claim comes from.

**Disclosure.** The site has no financial relationship with any pharmaceutical manufacturer, distributor, pharmacy, or telehealth platform. It earns no revenue from product referrals, prescription matchmaking, or affiliate links.

## How to read the manual

If this is a first visit, *Chapter 02 — Mechanism and Trials* (on /research) is the most concentrated dose of the underlying evidence. If a specific question brought the reader here, /faq is organized around the questions that bring most readers to a page titled *get tirzepatide* — including the questions about compounding, side effects, comparison with single-agonist GLP-1 therapy, and what happens when treatment stops. If the reader is sourcing claims for their own writing or research, /references lists every publication and FDA document cited on the site, each with a DOI or direct link to the primary source.

Every page on this site is also available as plain Markdown — just append `.md` to any URL, or read `/llms-full.txt` at the site root for the entire site concatenated into a single file.

---

An illustrated editorial digest of the published tirzepatide evidence — not a clinic, not a pharmacy, not a prescription.